Plant ID: NPO24087
Plant Latin Name: Psacalium peltatum
Taxonomy Genus: Psacalium
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
98714
Plant-of-the-World-Online:
n.a.
China; Mexico
DRD2; DRD1; | |
BCHE; ACHE; | |
MTOR; PKM; ALOX15; | |
STAT6; NFKB1; HIF1A; TP53; | |
HTT; THPO; LMNA; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.725E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.469E-08 | 2.968E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 2.968E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.227E-07 | 2.968E-04 | ACHE, BCHE, DRD2, HTT, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
BP | GO:0007610; behavior | GO:0008542; visual learning | 1.579E-07 | 3.092E-04 | DRD1, DRD2, HIF1A, MTOR |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.102E-07 | 4.862E-04 | ACHE, BCHE, DRD1, DRD2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.136E-07 | 4.862E-04 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.019E-06 | 7.154E-04 | ACHE, BCHE |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-06 | 1.129E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.054E-06 | 1.633E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.595E-06 | 1.779E-03 | HIF1A, LMNA, MTOR, TP53 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.565E-06 | 2.376E-03 | CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.416E-03 | CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 2.883E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.017E-05 | 3.354E-03 | DRD1, DRD2 |
BP | GO:0008152; metabolic process | GO:0046483; heterocycle metabolic process | 1.605E-05 | 4.723E-03 | ACHE, BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
BP | GO:0008152; metabolic process | GO:0006725; cellular aromatic compound metabolic process | 1.776E-05 | 4.896E-03 | ACHE, BCHE, CYP1A2, CYP2D6, DRD1, DRD2, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 2.841E-05 | 7.279E-03 | DRD1, DRD2 |
CC | GO:0044464; cell part | GO:0042995; cell projection | 4.013E-05 | 9.395E-03 | DRD1, DRD2, HIF1A, HTT, MTOR, PKM, SMN1, SMN2 |
BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 4.130E-05 | 9.566E-03 | BCHE, MTOR, PKM, TP53 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 4.196E-05 | 9.617E-03 | DRD1, MTOR, NFKB1, PKM, TP53 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.681E-05 | 1.311E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 7.890E-05 | 1.420E-02 | SMN1, SMN2 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.419E-04 | 2.208E-02 | CYP1A2, CYP2C19, CYP2D6, CYP3A4, DRD1, DRD2, HTT, LMNA, MTOR, STAT6 |
CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 1.543E-04 | 2.301E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.699E-08 | 1.937E-06 | CYP1A2, ALOX15, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.352E-07 | 2.291E-05 | PKM, TP53, HIF1A, MTOR |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.028E-07 | 2.291E-05 | CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.530E-05 | 4.360E-04 | DRD1, DRD2, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.086E-05 | 1.160E-03 | CYP2D6, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.193E-05 | 1.497E-03 | TP53, NFKB1, MTOR |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.082E-04 | 1.541E-03 | TP53, NFKB1, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.201E-05 | 1.368E-03 | CYP1A2, CYP3A4, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.419E-04 | 1.797E-03 | HIF1A, NFKB1, MTOR |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.818E-04 | 2.073E-03 | CYP2D6, ALOX15, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.121E-04 | 2.198E-03 | TP53, HIF1A, MTOR |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.507E-04 | 3.332E-03 | LMNA, TP53, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.758E-04 | 4.376E-03 | HIF1A, TP53, NFKB1, MTOR |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.966E-04 | 3.478E-03 | STAT6, TP53, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 4.996E-04 | 4.068E-03 | THPO, STAT6, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.034E-03 | 6.382E-03 | TP53, HIF1A, MTOR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.763E-04 | 6.382E-03 | DRD1, DRD2, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.064E-03 | 6.382E-03 | PKM, TP53, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.467E-03 | 8.244E-03 | NFKB1, MTOR |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.042E-03 | 6.382E-03 | PKM, MTOR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.624E-03 | 8.280E-03 | HIF1A, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.903E-03 | 8.280E-03 | TP53, MTOR |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.733E-03 | 8.280E-03 | ALOX15, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.961E-03 | 8.280E-03 | TP53, NFKB1 |
09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 1.903E-03 | 8.280E-03 | STAT6, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.519E-03 | 8.244E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.903E-03 | 8.280E-03 | CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.393E-03 | 9.406E-03 | TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 2.203E-03 | 8.968E-03 | NFKB1, MTOR |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
NA: NA | Inflammatory diseases | NA | DRD2; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Corneal vascularity | NA | DRD2; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
NA: NA | False perceptions | NA | DRD2; |
O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
NA: NA | Itching | NA | DRD2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
NA: NA | Peripheral vasoconstriction | NA | DRD2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
NA: NA | Vomiting | NA | DRD2; |
J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Malignant essential hypertension | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
NA: NA | Schizoaffective disorders | NA | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; DRD2; |
NA: NA | Hyperaemia | NA | DRD2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; |
I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |